Literature DB >> 27939618

Pharmaceutical salt of BM635 with improved bioavailability.

Giovanna Poce1, Sara Consalvi2, Martina Cocozza2, Raquel Fernandez-Menendez3, Robert H Bates3, Fátima Ortega Muro3, David Barros Aguirre3, Lluis Ballell3, Mariangela Biava2.   

Abstract

BM635 is a small molecule endowed with outstanding anti-mycobacterial activity (minimum inhibitory concentration of 0.12μM against M. tuberculosis H37Rv) identified during a hit-to-lead campaign. Its poor aqueous solubility together with its high lipophilicity led to low exposure in vivo. Indeed, the half-life in vivo of BM635 was 1h, allowing a reasonable maximum concentration (Cmax=1.62μM) and a moderate bioavailability (46%). The present study aimed to develop salt forms of BM635 with pharmaceutically accepted hydrochloric, methanesulphonic, phosphoric, tartaric, and citric acids to overcome these drawbacks. BM635 salts (BM635-HCl, BM635-Mes, BM635-PA, BM635-TA and BM635-CA) were evaluated for physicochemical as well as biopharmaceutical attributes.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  BM635; Drug development; MmpL3; Pharmaceutical salts; Tuberculosis

Mesh:

Substances:

Year:  2016        PMID: 27939618     DOI: 10.1016/j.ejps.2016.12.003

Source DB:  PubMed          Journal:  Eur J Pharm Sci        ISSN: 0928-0987            Impact factor:   4.384


  2 in total

1.  Novel Pyrazole-Containing Compounds Active against Mycobacterium tuberculosis.

Authors:  Giovanna Poce; Sara Consalvi; Giulia Venditti; Salvatore Alfonso; Nicoletta Desideri; Raquel Fernandez-Menendez; Robert H Bates; Lluis Ballell; David Barros Aguirre; Joaquin Rullas; Alessandro De Logu; Michelle Gardner; Thomas R Ioerger; Eric J Rubin; Mariangela Biava
Journal:  ACS Med Chem Lett       Date:  2019-09-18       Impact factor: 4.345

2.  Complete Cocrystal Formation during Resonant Acoustic Wet Granulation: Effect of Granulation Liquids.

Authors:  Ryoma Tanaka; Supisara Osotprasit; Jomjai Peerapattana; Kazuhide Ashizawa; Yusuke Hattori; Makoto Otsuka
Journal:  Pharmaceutics       Date:  2021-01-04       Impact factor: 6.321

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.